Shares in New York-based stem cell specialist BrainStorm Cell Therapeutics have fallen around half ahead of the opening bell, after the firm provided a negative 28 September 2023
Ahead of a panel meeting of the US Food and Drug Administration’s scientists, the agency’s briefing notes paint a pessimistic picture for the amyotrophic latera 26 September 2023
Florida-based central nervous system (CNS) specialist Relmada Therapeutics, has announced positive results from a late-stage trial of REL-1017. 21 September 2023
Swiss pharma firm Acino has acquired M8 Pharmaceuticals, a specialty biopharmaceutical company focused on licensing, marketing, and distributing innovative and 20 September 2023
The MAPS Public Benefit Corporation—a subsidiary of the Multidisciplinary Association for Psychedelic Studies—appears to be moving ever closer to an attention-g 15 September 2023
The HOPE trial—together with a clinical mechanism of action study—strengthens the case for Lundbeck's Lu AG09222, as additional data highlights the anti-pituita 14 September 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.